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The Role of Inflammatory Cytokines as Intermediates  
in the Pathway from Increased Adiposity to Disease
Marita Kalaoja 1,2,*, Laura J. Corbin 3,4,*, Vanessa Y. Tan 3,4,*, Ari V. Ahola-Olli5,6,7, Aki S. Havulinna8, 
Kristiina Santalahti9, Niina Pitkänen10, Terho Lehtimäki11,12, Leo-Pekka Lyytikäinen11,12, Emma Raitoharju11,12,  
Ilkka Seppälä11,12, Mika Kähönen13,14, Samuli Ripatti7,15,16, Aarno Palotie5,6,7,16,17,18, Markus Perola7,8,  
Jorma S. Viikari19,20, Sirpa Jalkanen9, Mikael Maksimow9, Veikko Salomaa8, Marko Salmi9, Olli T. Raitakari10,21,22, 
Johannes Kettunen1,2,8,**, and Nicholas J. Timpson 3,4,**
Objective: This study aimed to investigate the role of cytokines as inter-
mediates in the pathway from increased adiposity to disease.
Methods: BMI and circulating levels of up to 41 cytokines were measured 
in individuals from three Finnish cohort studies (n = 8,293). Mendelian ran-
domization (MR) was used to assess the impact of BMI on circulating cy-
tokines and the impact of BMI-driven cytokines on risk of obesity-related 
diseases.
Results: Observationally, BMI was associated with 19 cytokines. For 
every SD increase in BMI, causal effect estimates were strongest for 
hepatocyte growth factor, monocyte chemotactic protein-1 (MCP-1), 
and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and 
were as ratios of geometric means 1.13 (95% CI: 1.08-1.19), 1.08 (95% 
CI: 1.04-1.14), and 1.13 (95% CI: 1.04-1.21), respectively. TRAIL was as-
sociated with a small increase in the odds of coronary artery disease 
(odds ratio: 1.03; 95% CI: 1.00-1.06). There was inconsistent evidence for 
a protective role of MCP-1 against inflammatory bowel diseases.
Conclusions: Observational and MR estimates of the effect of BMI on 
cytokine levels were generally concordant. There was little evidence for 
an effect of raised levels of BMI-driven cytokines on disease. These find-
ings illustrate the challenges of MR when applied in the context of mo-
lecular mediation.
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What is already known?
►	Chronic low-grade inflammation is a 
common feature of obesity and obesity-
related conditions such as insulin resist-
ance and type 2 diabetes.
►	Persistent dysregulation of the body’s 
inflammatory response has been im-
plicated in several diseases, including 
cardiovascular disease, diabetes, and 
cancer.
What does this study add?
►	We extend knowledge of the impact of 
increased adiposity (measured using 
BMI) on inflammatory profile beyond the 
“usual suspects” to 41 directly quanti-
fied cytokines and growth factors, pro-
viding estimates of effect derived from 
both observational and causal analyses.
►	Our findings contribute to an emerging 
picture of a complex role for cytokines in 
immune-mediated diseases and provide 
suggestive evidence for a detrimental 
role of TRAIL in coronary artery disease.
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Obesity is a major public health problem, the burden of which extends across multiple 
organ systems. Increased adiposity, frequently assessed using BMI, has been directly im-
plicated in the development of diseases such as cardiovascular disease (1), diabetes (1), and 
some cancers (2). However, the mechanisms by which raised BMI affects disease are not 
fully understood. Studying intermediate phenotypes reflective of physiological function 
can provide valuable insight into such complicated etiologic disease pathways as these (3).
Chronic low-grade inflammation as characterized by abnormal cytokine production and 
the activation of a network of inflammatory signaling pathways is a common feature of 
obesity and obesity-related conditions, such as insulin resistance and type 2 diabetes (4). 
Although inflammation is an important part of the human immune response and plays 
a key role in protecting the body against pathogens, inflammation can also be harmful. 
Persistent dysregulation of the body’s inflammatory response has been implicated in sev-
eral diseases, including cardiovascular disease (5), diabetes (6,7), and cancer (8,9). In 
obesity, inflammatory signals appear to disrupt insulin action, leading to insulin resis-
tance (10), and it has been hypothesized that the development of a systemic inflammatory 
state in those with overweight contributes to obesity-associated pathophysiological con-
sequences (11).
How might these results change the 
direction of research or the focus of 
clinical practice?
►	C-reactive protein is likely to remain a 
key biomarker for systemic inflammation 
in patients with increased adiposity, but 
as we begin to better understand their 
functions, other cytokines may serve 
as markers for more specific adiposity-
related pathophysiology.
►	Methodological developments are re-
quired in order to increase our confidence 
in the use of Mendelian randomization to 
evaluate the causal effect on disease of 
signaling molecules, such as cytokines, 
because of the likely pleiotropic nature 
of instruments.
As signaling molecules with a key role in regulating inflammation, 
circulating cytokine levels provide a useful readout of inflammatory 
function. Tumor necrosis factor alpha was the first proinflammatory 
cytokine to be associated with obesity-linked insulin resistance (12). 
Since then, a number of other proinflammatory cytokines, including 
several interleukins (ILs), have been identified as potential mediators 
in the systemic inflammatory response to obesity (13). However, with 
most studies of increased adiposity and inflammation focusing on a 
small number of relatively well-known proinflammatory molecules, 
the relevance of many other cytokines to this pathway remains uncer-
tain. Furthermore, it is understood that in observational analyses, even 
with careful study design, confounding, reverse causation, and other 
biases limit the extent to which causal inference is possible (14). One 
approach that is useful in trying to address these problems is the use 
of genetic association results within a Mendelian randomization (MR) 
framework (14). In MR analyses, genetic variants act as an approxima-
tion to instrumental variables (IVs) to enable an evaluation of the causal 
effect of the exposure on the outcome (14). MR analyses, in which BMI 
represents the exposure and C-reactive protein (CRP) the outcome, 
were among the first to use this approach to provide evidence in sup-
port of a causal role for increased adiposity in promoting low-grade 
inflammation (15). However, there appear to be few, if any, examples 
of the same approach being applied to collections including multiple 
cytokine measurements.
More commonly, MR studies have been undertaken looking at the 
downstream effects of specific inflammatory molecules. Because of the 
need for genetic variants to act as proxies for the exposure, such anal-
yses have been limited to the study of cytokines and other inflamma-
tory biomarkers for which these exist. CRP has been the focus of much 
attention, but despite its strong association with inflammation and its 
observational association with disease, evidence for a causal effect of 
CRP on disease is limited. One proposed explanation for this, given in 
the context of breast cancer, is that CRP is only linked to disease as a 
“cytokine reporter,” hence there is no relationship to non–“responsive- 
mode” variation in CRP levels driven by polymorphisms in the 
gene (16). In contrast, a number of MR studies focused on ILs as an 
exposure, have found evidence for a causal effect of IL-6 and/or IL-1 
on a small number of cardiovascular and autoimmune-type diseases, as 
well as schizophrenia (17-20).
Therefore, although evidence on the possible role of inflammation 
in pathologies related to increased adiposity is accumulating, the 
relevance of many less well-characterized cytokines is unclear. The 
recent publication of a genome-wide association study (GWAS) for 
41 cytokines (21) conducted in a Finnish population represents an 
advance in this field, enabling a much broader range of cytokines and 
their impact on disease to be assessed. Within three population-based 
studies, we employ a two-step MR analysis (22) to investigate the 
relationship between BMI, circulating levels of the 41 cytokines, and 
disease. Included in this work is a rerun of the published cytokine 
GWAS (21), removing BMI as a covariate from the model, which 




This study has three main components as outlined in Figure 1: (1A) 
analysis of the observational association between BMI and cytokines 
using individual level data from three Finnish cohort studies; (1B) anal-
ysis of the causal effect of BMI on cytokines in a one-sample MR frame-
work, using the same individual level data (an equivalent two-sample 
style MR analysis is presented in the online Supporting Information 
Methods); and (2) analysis of the causal effect of BMI-driven cyto-
kines on relevant disease outcomes in a two-sample MR framework. 
By way of comparison, results for the more widely studied CRP are 
presented alongside those for the inflammatory cytokines, although it 
should be noted that CRP was measured independently from the cyto-
kines. Herein, the term “inflammation-related variables” will be used to 
describe the set of inflammatory cytokines plus CRP.
Study populations
Individual level data analyses (1A and 1B in Figure 1) were examined in 
a cross-sectional study within the Cardiovascular Risk in Young Finns 
Study (YFS) and the FINRISK 1997 and 2002 cohorts. YFS (https://
young finns study.utu.fi/) is a multicenter follow-up study with randomly 
chosen subjects from the Finnish cities of Helsinki, Kuopio, Oulu, 
Tampere, and Turku and their rural surroundings. FINRISK surveys 
Obesity
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(https://thl.fi/en/web/thlfi-en/resea rch-and-exper twork/ popul ation-studi 
es/the-natio nal-finri sk-study) are population-based cross-sectional stud-
ies conducted every 5 years to monitor the levels of chronic disease risk 
factors in Finland. Each survey includes 25- to 74-year-old randomly 
chosen subjects from five geographical areas of Finland. For further de-
tails of the cohorts used, see the Supporting Information Methods. The 
present study includes unrelated individuals from these cohorts with 
both cytokine measurements and genome-wide genotype data. Further 
details regarding cytokine quantification, genotyping, and subsequent 
imputation can be found in the Supporting Information Methods and 
are as described previously (21). In YFS (n = 1,980) and FINRISK 
2002 (n = 1,705), 48 cytokines were measured using Bio-Rad’s pre-
mixed Bio-Plex Pro Human Cytokine 27-plex and 21-plex assays. In 
FINRISK 1997 (n = 4,608), a custom-selected 20-cytokine plex was 
used. Cytokines with >90% of values missing were excluded from all 
analyses. A full list of the measured cytokines is provided in Supporting 
Information Table S1. These cohort data were also used to generate a 
revised version of the previously published GWAS of 41 inflammatory 
cytokines (21), without fitting BMI as a covariate in the model (see the 
Supporting Information Methods). This was done in order to avoid the 
possibility of collider bias in the subsequent two-sample MR analysis 
(step 2 in Figure 1). Data on several potential confounders were used in 
sensitivity analyses (see the Supporting Information Methods).
Selection of genetic variants for MR analyses
Ninety-seven independent single-nucleotide polymorphisms 
(SNPs) that were associated with BMI at genome-wide signifi-
cance (P < 5 × 10−8) were selected from a meta-GWAS for BMI 
(n = 339,224) (23). The genetic instruments for the BMI-associated 
cytokines taken forward to analysis step 2 were selected based on 
the results of our rerun of the previously published GWAS of 41 in-
flammatory cytokines (n = 8,337) (21). To maximize the number of 
available instruments for each cytokine, a list of cytokine-associated 
SNPs (P < 5 × 10−8) was first cross-matched to the corresponding 
GWAS summary statistics for each disease outcome in turn. Then, 
taking the subset of SNPs that were present (or had a suitable proxy 
with linkage disequilibrium [LD], r2 > 0.8) in both data sets, an in-
dependent set of instruments was generated using an LD clumping 
procedure with an r2 threshold of 0.01 (see Supporting Information 
Methods for full details). This procedure was implemented using the 
TwoSampleMR R package (24) (version 0.4.26).
For CRP, we used as instruments a set of three SNPs (rs3093077 [A/C], 
rs1205 [T/C], and rs1130864 [A/G]) that has previously been shown to 
represent common variation within the CRP gene associated with dif-
ferent circulating levels in populations of European descent (25).
Statistical analyses
In the observational analysis and first step of the MR (1A and 1B in 
Figure 1), we penalized results given the 41 tests undertaken (P < 0.001 
can be considered equivalent to P < 0.05). No such penalization was 
applied in the second step of the MR in which we took P < 0.05 as evi-
dence of association.
Part 1A: The observational association between BMI and the 
inflammation-related variables. Observational associations of 
BMI with levels of 41 cytokines and CRP (1A in Figure 1) were assessed 
in the three cohorts using linear regression. Cytokine distributions were 
first normalized with rank-based inverse normal transformation (RNT). 
The transformed phenotypes were then regressed on age, sex, and 10 
principal components and model residuals extracted. A second RNT 
was then performed on the residuals. Associations of residuals with 
BMI were assessed using linear regression. CRP measures underwent 
the same transformation and covariate adjustment process. Effect 
estimates for cytokines and CRP are given in normalized SD units per 
z-scored SD higher BMI. All observational analyses were conducted 
separately in the three cohorts and combined in a fixed effects meta-
analysis. Supplementary analyses relating to potential confounders are 
described in the Supporting Information Methods.
Part 1B: One-sample MR analysis of the effect of BMI on the 
inflammation-related variables. A one-sample MR analysis (1B 
in Figure 1) was carried out using a weighted genetic risk score (GRS) 
generated based on the 97 SNPs selected as instruments for BMI (see 
the Supporting Information Methods). Two-stage least squares analysis 
Figure 1  Study overview. (1A) represents the analysis of the observational association between BMI and the 
inflammation-related variables, whereas (1B) represents the one-sample Mendelian randomization (MR) analysis 
of the effect of BMI on the inflammation-related variables. (2) Represents the two-sample MR analysis of the 
effect of BMI-driven inflammation-related variables on relevant disease outcomes. [Color figure can be viewed at 
wileyonlinelibrary.com]
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was used to obtain estimates of the association of BMI with each 
inflammatory variable (using the same RNT residuals as were derived 
previously). Analyses were conducted separately in the three cohorts 
using the ivreg-function from the R package AER (26) and then were 
combined in a meta-analysis using the rma-function from the R package 
metaphor (27). Effect estimates are given in normalized SD units per 
SD higher BMI. We compared the instrumental variable estimates with 
those from observational linear regression using the Durbin form of 
the Durbin-Wu-Hausman statistic (28). For cytokines in which one-
sample MR yielded suggestive evidence for BMI effect (P < 0.05), 
analyses were rerun using natural log-transformed values (adjusting for 
age and sex) to aid interpretation (1 was added to each value prior to 
transformation to account for zero values).
For completeness, the causal associations between BMI and lev-
els of inflammatory variables assessed in the one-sample framework 
described above were also evaluated using a two-sample framework. 
Causal estimates were derived using the Wald ratio method and esti-
mates were combined using the inverse-variance weighted method. Full 
details of this analysis, including sensitivity analyses, are presented in 
the Supporting Information Methods.
Part 2: Two-sample MR analysis of the effect of BMI-driven 
inflammation-related variables on relevant disease outcomes. The 
criteria for inclusion in this second step, two-sample MR analysis (step 
2 in Figure 1) was P < 0.001 in the first step analysis, such that only 
those cytokines for which there was strongest (a priori) evidence of BMI 
effect were taken forward. In this analysis, SNP-exposure associations 
were taken from our rerun of the 41-cytokine GWAS and for CRP, from 
a recent meta-GWAS (n > 200,000) (29). SNP-outcome associations for 
relevant disease outcomes were derived from a number of published 
GWASs conducted in populations of European or mixed ancestry. There 
was no sample overlap between exposure and outcome data sources.
Diseases were considered relevant if there was existing observational 
evidence of their association with BMI and/or cytokines. From this 
selection, diseases were included in the analysis if there existed, within 
MR-Base (24), summary statistics for a GWAS of that disease with 
a sample size of at least 50,000 subjects (Supporting Information 
Table S2). Diseases included as outcomes were coronary artery disease 
(CAD), type 2 diabetes, inflammatory bowel disease (IBD) (plus Crohn 
disease [CD] and ulcerative colitis [UC] as separate traits), rheumatoid 
arthritis, Alzheimer disease, schizophrenia, breast cancer, and ovarian 
cancer. For IBD and associated traits, we extracted results from both 
Immunochip-based and GWAS-based meta-analyses.
For each instrument (SNP), causal estimates were derived using 
the Wald ratio method, and when multiple instruments were avail-
able, estimates were combined using the inverse-variance weighted 
method to provide a single causal estimate of the exposure-outcome 
association (30). Methods typically used to test for pleiotropy, such 
as MR-Egger (31), were not conducted as these lack power with 
small numbers of SNPs. However, heterogeneity tests were used to 
give an indication of the variability of the estimates across SNPs. 
Statistical analyses were performed using R version 3.5.3.
Results
Baseline characteristics of the participants in YFS and in FINRISK 
1997 and 2002 are shown in Table 1 and cytokine summary statistics 
are shown in Supporting Information Table S3. A total of 8,293 indi-
viduals with BMI and cytokines measured were included in this study 
from across the three cohorts (YFS, FINRISK 1997, and FINRISK 
2002). The mean age (SD) of individuals in YFS, FINRISK 1997, and 
FINRISK 2002 was 38 (5), 48 (13), and 60 (6) years, respectively. The 
mean BMI (SD) of individuals in YFS, FINRISK 1997, and FINRISK 
2002 was 26 (5), 27 (5), and 28 (4) kg/m2, respectively.
Results from the rerun of the previously published GWAS of 41 
inflammatory cytokines are available at the University of Bristol data 
repository, data.bris, at: https://doi.org/10.5523/bris.3g3i5 smggh p0s2u 
TABLE 1 Characteristics of participants in the three cohorts
Young Finns Study, 
N = 1,980




Continuous variables Total, N Mean (SD) Mean (SD) Mean (SD)
Age (y) 8,293 37.7 (5.0) 47.8 (13.3) 60.3 (6.1)
BMI (kg/m2) 8,293 26.0 (4.8) 26.6 (4.5) 27.9 (4.5)
Alcohol (g/wk) 8,091 80.1 (121.1) 70.9 (126.4) 78.2 (135.1)
C-reactive protein (mg/L) 8,227 1.8 (3.8) 2.5 (6.1) 2.9 (6.2)
Categorical variables N % (N) % (N) % (N)
Gender
Male 4,059 45.7 (905) 49.9 (2,300) 50.1 (854)
Female 4,234 54.3 (1,075) 50.1 (2,308) 49.9 (851)
Socioeconomic status
Low 1,926 4.9 (96) 29.2 (1,334) 29.8 (496)
Average 3,422 70.7 (1,393) 32.7 (1,493) 32.2 (536)
High 2,856 24.4 (481) 38.2 (1,745) 37.9 (630)
Smoking
Current 1,825 18.6 (365) 25.1 (1,150) 18.3 (310)
Ex/never 4,813 81.4 (1,600) 74.9 (3,427) 81.7 (1,386)
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vm1do flkx9x. Removing BMI as a covariate in the model had a minor 
impact on the GWAS results. The correlations between betas derived 
from the two models (with and without BMI fitted) were between 0.77 
and 1 (median 0.99). Of the 27 SNP-cytokine associations previously 
reported (21), all were present in the BMI-unadjusted results with sim-
ilar betas (Supporting Information Figure S1).
Figure 2 Observational (Observ.) and Mendelian randomization (MR) associations of BMI and inflammation-related variables. Effect estimates are 
given in normalized SD units per 1-SD-higher BMI. Estimates represent meta-analyzed results. (A) CRP result (YFS, FINRISK 1997, FINRISK 2002). 
(B) Results for cytokines available in all three cohorts (YFS, FINRISK 1997, FINRISK 2002). (C) Results for cytokines available only in two cohorts 
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Part 1A: The observational association between 
BMI and the inflammation-related variables
The age- and sex-adjusted observational associations between BMI and cy-
tokines for YFS, FINRISK 1997, and FINRISK 2002 are shown in Figure 2. 
In meta-analyses, BMI was associated with 19 cytokines (CTACK [C-C 
motif chemokine 27], eotaxin, hepatocyte growth factor [HGF], IL-10, IL-
12p70, IL-13, IL-16, IL-18, IL-1ra, IL-2ra, IL-6, IL-7, IL-8, IP-10, mono-
cyte chemotactic protein-1 [MCP-1], macrophage migration inhibitory 
factor [MIF], macrophage inflammatory protein 1-beta [MIP-1β], tumor 
necrosis factor–related apoptosis-inducing ligand [TRAIL], and vascular 
endothelial growth factor [VEGF]) and CRP (Figure 2). Estimates were 
largely consistent across cohorts (Supporting Information Figure S2) and 
with and without additional adjustment for potential confounding factors 
(Supporting Information Figure S3). Confounder association results are 
presented in the Supporting Information (Tables S4-S7).
Part 1B: One-sample MR analysis of the effect of 
BMI on the inflammation-related variables
A one unit increase in the BMI GRS was associated with a 4.36 kg/m2  
(95% CI: 3.78- 4.93; P = 7.34 × 10−50) increase in BMI (Supporting 
Information Table S9), giving a median F-statistic of 66 in YFS, 102 in 
FINRISK 1997, and 29 in FINRISK 2002 (Supporting Information Table 
S10). When compared with the relationship between observed BMI and 
potential confounders (Supporting Information Table S4), the associa-
tion of the BMI GRS with confounders was substantially diminished 
(Supporting Information Table S9). The inflammation-related variables 
with the strongest evidence of BMI effect were CRP, HGF, MCP-1, and 
TRAIL (Figure 2, Supporting Information Figure S4). Effect sizes de-
rived by exponentiating the natural log-transformed betas presented in 
Supporting Information Table S11 and, therefore, expressed as the ratio 
of geometric means of circulating CRP, HGF, MCP-1, and TRAIL per 
1-SD increase in BMI were 1.39 (95% CI: 1.27-1.51), 1.13 (95% CI: 
1.08-1.19), 1.08 (95% CI: 1.04-1.14), and 1.13 (95% CI: 1.04-1.21), 
respectively; this approximates to an increase in circulating CRP of 
0.44 mg/L, and an increase in HGF, MCP-1, and TRAIL of 50.9 pg/mL, 
2.8 pg/mL and 14.7 pg/mL, respectively. There was no clear evidence 
of a departure of instrumental variable-derived estimates from those de-
rived from observational analyses (Supporting Information Table S10). 
A further seven cytokines had causal effect estimates that were different 
from zero but failed to satisfy our inclusion criteria for the step two 
analysis (IL-12p70, IL-6, IL-7, IP-10, MCP-3, MIP-1β, and VEGF).
Part 2: Two-sample MR analysis of the effect of 
BMI-driven inflammation-related variables on 
relevant disease outcomes
Causal effects on disease were estimated for the four inflammation- 
related variables, which met the inclusion criteria for the second step 
(CRP, HGF, MCP-1, and TRAIL). Overall, we identified 3, 6, and 33 
SNPs as instruments for HGF, MCP-1, and TRAIL, respectively; effect 
estimates for these and the three CRP SNPs used are shown in Supporting 
Information Table S12. The actual set of instruments used in each analysis 
was dependent on which SNPs were present in the relevant disease GWAS 
(see Supporting Information Tables S13-S16 for lists of instruments used 
in each analysis). We observed considerable heterogeneity in the effect 
estimates for rs12075 on MCP-1 across the three cohorts (Supporting 
Information Table S17). We hypothesize that the lack of association in the 
FINRISK 2002 cohort is likely due to the use of heparin as an anticoag-
ulant (32). However, given the relatively small contribution of this cohort 
to the total sample, we anticipate that the impact of this difference on the 
meta-analyzed SNP effect estimate used in the MR is low.
For CRP, we saw evidence of association with schizophrenia only, with 
an odds ratio (OR) of 0.91 (95% CI: 0.84-0.99; P = 0.03) per unit change 
in natural log-transformed CRP levels (Figure 3, Supporting Information 
Table S18). For MCP-1, we detected an association with IBD using 
Immunochip summary statistics such that the ORs of disease per nor-
malized SD change in MCP-1 was 0.87 (95% CI: 0.79-0.95; P = 0.003) 
(Figures 3 and 4A, Supporting Information Table S18). Corresponding 
effect estimates for the IBD subtypes of CD and UC were similar (0.91 
[95% CI: 0.81-1.02; P = 0.09] and 0.84 [95% CI: 0.74-0.96; P = 0.008], 
respectively) (Figures 3 and 4B-4C, Supporting Information Table S18). 
Effect estimates derived from the GWAS data sets for these same dis-
eases did not show the same protective effect. Results were largely con-
sistent with those from the Immunochip analysis for the single shared 
SNP (rs2036297), but overall estimates for IBD and UC were null, 
whereas the association between MCP-1 and CD (OR 1.2; 95% CI: 1.05-
1.38; P = 0.01) was in the opposite direction to that observed using the 
Immunochip data set (Figures 3 and 4, Supporting Information Table 
S18). We found evidence of a small effect of TRAIL on CAD with OR of 
1.03 (95% CI: 1.00-1.06; P = 0.04) using the CARDIoGRAMplusC4D 
GWAS data but no apparent effect when using the smaller European-
only CARDIoGRAM GWAS data (OR 1.00; 95% CI: 0.94-1.07; 
P = 0.91) (Figure 3, Supporting Information Figure S7 and Table S18).
Discussion
In this study, we compared estimates from observational analyses with 
those from MR (1) to allow inference to be drawn about the causal 
relationship between adiposity and inflammation and (2) to evaluate 
the subsequent impact of BMI-driven cytokines on relevant disease out-
comes. We can now expand our understanding of the impact of BMI on 
the inflammatory profile beyond the “usual suspects” (e.g., CRP, IL-6) 
in a systematic and robust way that makes use of new data. Using a 
two-step MR design, we were able to partially replicate previous asso-
ciations and contribute new knowledge. Overall, we saw little evidence 
for a detrimental effect on health of raised levels of the BMI-driven 
cytokines examined. However, we cannot rule out the possibility that 
these cytokines may have small effects on disease risk that are not de-
tectable here because of limited power. Our findings contribute to the 
emerging literature that points toward a complex role for cytokines in 
immune-mediated diseases (33) and provide suggestive evidence for a 
detrimental role of TRAIL in CAD.
In observational analyses, the majority of cytokines within the IL 
subclass showed a positive association, with BMI having the stron-
gest signal observed for IL-18. Outside of the IL subclass, strong 
effects were also observed for HGF, TRAIL, and MIP-1β. Although 
the majority of cytokines were found to be positively associated 
with BMI, both eotaxin and CTACK (CCL27) showed decreased 
levels with increased BMI. In the one-sample MR framework, evi-
dence was strongest for a BMI effect on HGF, MCP-1, and TRAIL. 
These effects are commensurate with reductions in both HGF (34) 
and MCP-1 (35) seen following weight loss. Meanwhile, TRAIL has 
previously been proposed as having a role in obesity and weight gain 
(36) and has been linked to a proinflammatory response in adipocytes 
(37). Although the effect estimates derived from the MR analysis 
were in most cases similar to those derived observationally, the rel-
ative reduction in power and the conservative nature of our multiple 
testing correction meant that only three cytokines met the criteria 
set for inclusion in the second step. Retrospective power analyses 
(38) showed that, when we had data for three cohorts (approximately 
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8,000 individuals), our analyses had 80% power to detect effect sizes 
in excess of 0.19 SD (α = 0.05), which suggests reasonable power 
across the range of effects seen observationally (0.05-0.27 SD). 
However, when data were available for only two cohorts (approxi-
mately 3,500 individuals), only the largest effect sizes (>0.30 SD) 
were likely detectable with the same level of statistical confidence. 
We would anticipate that with greater statistical power, several other 
cytokines would be added to the list of BMI-associated molecules.
Restricting our attention to HGF, MCP-1, and TRAIL, we went on to 
consider whether these cytokines could be causally related to BMI-
associated disease outcomes. Increased levels of TRAIL appeared to 
be associated with a small increase in the odds of CAD but only when 
using the larger CARDIoGRAM-plusC4D GWAS result. Although 
marginal, particularly within the context of the number of tests per-
formed, this effect is of interest given the complex relationship of 
TRAIL and its receptor with atherosclerosis and vascular biology. 
TRAIL and its receptors are expressed in both physiological and 
pathological arterial walls (39). There is evidence that TRAIL sig-
naling can either protect against or promote the formation of athero-
sclerotic lesions (40). The complex relationship of TRAIL with CAD 
may be due to the existence of different receptor types that either 
initiate apoptosis (TRAIL-R1/DR4 and R2/DR5) or promote apop-
tosis by acting as decoy proteins for TRAIL binding (TRAIL-R3/
DcR1, R4/DcR2, and osteoprotegerin) (40). Our observation that 
TRAIL does not appear to have a downstream effect on metabolic 
disease is important given conflicting evidence concerning its role 
in inflammatory diseases such as type 2 diabetes (37). In response to 
studies (mainly mouse work) showing a protective effect of TRAIL 
against increased adiposity/diabetes, both TRAIL and its receptor 
TRAIL-R have been proposed as therapeutic targets. However, the 
lack of association of TRAIL with any downstream metabolic dis-
ease here suggests more research is needed to fully understand the 
role of this molecule.
Using summary statistics from a large Immunochip study, MCP-1 
showed consistent associations with IBD and its subtypes (UC and 
CD), such that increased levels of the cytokine appear to decrease 
odds of disease. IBDs are immunologically mediated diseases char-
acterized by chronic relapsing inflammation of the intestine. MCP-1 
is a chemokine that plays an important role in the recruitment of 
monocytes and macrophages from the bloodstream to inflamed 
tissues. Early studies involving intestinal biopsy specimens from 
patients with IBD showed increased MCP-1 mRNA expression in 
inflamed tissues, which in some cases was considered to be evidence 
for a pathological role of MCP-1 in the disease (41,42). However, 
more recently, an immunosuppressive role for MCP-1 has been 
proposed and its therapeutic potential explored (43). This appar-
ent uncertainty in the role of MCP-1 in IBD is also reflected in the 
MR results in this study. Using summary statistics derived instead 
from the GWAS study of IBD, UC, and CD, no effect was seen of 
MCP-1 on IBD and UC, whereas for CD, increased levels of MCP-1 
were found to increase odds of disease. These contradictory results 
point to important limitations of MR in this context. Cytokines are 
Figure 3 Mendelian randomization associations of BMI-driven inflammation-related variables and disease outcomes. Estimates correspond to the odds ratio (OR) per unit 
increase in natural log-transformed CRP or per normalized SD increase in HGF, MCP-1, and TRAIL. [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 4 SNP-specific Mendelian randomization associations for MCP-1 and inflammatory bowel disease 
(IBD), ulcerative colitis (UC), and Crohn disease (CD). (A) SNP-specific associations between circulating 
MCP-1 and odds of IBD. Estimates correspond to the odds ratio for IBD using either Immunochip data 
(N cases = 31,665, N controls = 33,977) or GWAS data (N cases = 12,882, N controls = 21,770) per normalized 
SD increase in circulating MCP-1 (N = 8,337) levels. (B) SNP-specific associations between circulating 
MCP-1 and odds of UC. Estimates correspond to the odds ratio for UC using either Immunochip data 
(N cases = 13,768, N controls = 33,977) or GWAS data (N cases = 6,968, N controls = 20,464) per normalized 
SD increase in circulating MCP-1 (N = 8,337) levels. (C) SNP-specific associations between circulating 
MCP-1 and odds of CD. Estimates correspond to the odds ratio for CD using either Immunochip data 
(N cases = 17,897, N controls = 33,977) or GWAS data (N cases = 5,956, N controls = 14,927) per normalized 
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a network of signaling molecules and it would be naïve to imagine 
that we can instrument single cytokines and describe their impact on 
disease in isolation.
One specific issue potentially complicating interpretation is pleiot-
ropy. The idea that genetic variants are associated with levels of sin-
gle cytokines seems unrealistic and instead what we expect is that 
pleiotropy (i.e., genetic variants associated with more than one cyto-
kine in pathway effects or as independent and horizontal events) is 
more likely. If pleiotropy is present in the form of independent path-
way effects (horizontal), our MR estimates can be biased in specific 
conditions (44). Many of the SNPs we use as instruments for the 
cytokines are in trans and as such, we presume their effect must go 
through several pathways, opening the possibility that those pathways 
influence the outcome independently of the target exposure (44). The 
inconsistency that we see in results from the GWAS and Immunochip 
studies for MCP-1 and IBD/UC/CD may be indicative of this issue. 
The instruments identified for MCP-1 include variants in or near 
genes encoding chemokine receptors that have multiple ligands. 
Two SNPs present as instruments only in the GWAS-based analysis 
(rs12075 in ACKR1 and rs2228467 in ACKR2) generated estimates in 
the opposite direction to most other variants leading to heterogeneity 
in the estimates (P < 0.10 for IBD and UC). As anticipated, given 
their function, we found evidence that rs12075 and rs2228467 are 
associated with eight and four other cytokines (P < 0.05) in our data, 
respectively. One potential strategy for reducing the impact of pleiot-
ropy could be to restrict analyses to cis variants only, as these effects 
are likely closer to the biology of the molecular trait because of their 
genomic proximity. However, this would reduce the power of the MR 
because of the small number of instruments that remain.
Although various strategies have been developed to assess and mini-
mize the impact of pleiotropy in MR (44), this is just one of a number 
of possible sources of bias, another being latent population structure. 
It seems likely that at least some of the disparities we see in results 
both within and out with the realm of MR reflect properties of the 
instruments employed. Other more subtle issues also exist. In partic-
ular, there is potential for SNP-cytokine associations to vary because 
of blood collection protocols (as seen here for rs12075 and MCP-
1) and the possibility that SNP-cytokine associations are driven by 
the impact of genetic variants on cytokine conformation rather than 
by actual changes in concentration. Furthermore, for two-sample 
MR analyses to be valid, the two samples should be from the same 
underlying population. We did not use sex-specific cytokine instru-
ments for the female-specific cancers, which could lead to biased 
estimates; however, we did not find evidence of marked sex-differ-
ences for the cytokine instruments (Supporting Information Table 
S19A-S19B). It should also be noted that this work is conducted in 
Finnish and European populations and that further work is needed to 
evaluate the extent to which our findings are generalizable to other 
populations, including those of wider European and non-European 
ancestry.
In this study of the effect of variation in cytokine levels on disease, 
given N = 50,000 (our threshold for inclusion) and assuming a 1:2 
ratio of cases to controls, we had 80% power to detect an OR of 
1.21, 1.19, and 1.05 for HGF, MCP-1, and TRAIL, respectively 
(45). In this context, we do not see strong evidence for associations 
between BMI-driven cytokines and risk of a collection of diseases 
often associated with increased adiposity. Although this result could 
be interpreted as evidence that inflammation is not a mediator of the 
relationship between increased adiposity and the set of disease out-
comes studied, it is important to consider the context of these find-
ings. In MR, results can be interpreted as a reflection of the impact 
of lifelong (chronic) exposure to a risk factor (in this case, raised 
cytokine levels) on disease. Taken in this way, results are not able 
to tell us about the role of these same cytokines when in a state of 
acute or chronic inflammation. For example, although we see some 
evidence for a protective effect against IBD of chronically raised lev-
els of MCP-1, the increase in MCP-1 levels that reflect the inflam-
matory response to increased adiposity are unlikely to have the same 
downstream consequences. Furthermore, this work concentrates on 
circulating levels of cytokines, though it is likely that tissue-specific 
expression of these molecules is important.
This study is the first MR analysis to estimate the causal effect of BMI 
on a comprehensive panel of inflammatory cytokines and the subse-
quent impact of BMI-driven cytokines on relevant disease outcomes. 
Observationally, we see a broad signature of increased BMI on circulat-
ing cytokines. The concordance we observe between observational and 
MR estimates of the effect of BMI on circulating cytokines suggests a 
biologically meaningful relationship between BMI and inflammation 
and minimal influence of confounders. Although circulating cytokines 
provide a useful readout of the inflammatory response to increased adi-
posity, in order to provide a definitive answer to the question of the 
role of cytokines in disease, results from several different approaches 
with unrelated sources of bias, including challenge/intervention studies, 
need to be integrated.O
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